The proportion of PD-1+ of CLA+CD39+ Treg EM cells was significantly higher in non-responders as well as in SS patients, and we found evidence of peripheral CD8+ T cell activation differentiating both therapeutic response and disease status (Figures 5F and 6A). This evidence concerns the gene ENTPD1 and synovial sarcoma.